Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
Meanwhile, supply shortages of weight-loss drugs like Zepbound and Ozempic have led to a surge in knockoff "compounder" drugs ...
New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...
Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
There's buzz around certain type 2 diabetes drugs, which not only help regulate blood sugar but can also lead to significant ...
Eli Lilly's ... weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread ...